Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 12 de 12
Filter
1.
Thromb J ; 19(1): 40, 2021 Jun 02.
Article in English | MEDLINE | ID: mdl-34078390

ABSTRACT

BACKGROUND: Altered mean platelet volume (MPV) and plasma albumin has been reported in type 2 diabetes (T2D). MPV is suggested to predict cardiovascular risk but there is a lack of evidence for associations between MPV and platelet adhesion. Plasma albumin and magnesium are other factors reported to influence thrombotic risk. The objectives of this study were to assess the association between platelet adhesion and plasma factors with a potential role to affect platelet activation. METHODS: Blood was collected from 60 T2D patients and 60 healthy controls. Platelet adhesion to different protein surfaces induced by various soluble activators were measured in microplates. MPV, albumin and magnesium were analysed together with additional routine tests. RESULTS: Despite normal levels, plasma albumin significantly correlated with adhesion of T2D platelets but not with controls. There was a significant association between MPV and platelet adhesion in both groups, but association was smaller in T2D. Levels of glucose, HbA1c or magnesium did not correlate with platelet adhesion. CONCLUSIONS: Plasma albumin was associated with platelet adhesion in T2D suggesting that albumin may be a factor to consider upon cardiovascular risk assessment. MPV was more associated with the level of platelet adhesion in healthy individuals than in well-controlled T2D patients.

2.
Diab Vasc Dis Res ; 18(2): 14791641211002470, 2021.
Article in English | MEDLINE | ID: mdl-33775157

ABSTRACT

BACKGROUND: Tissue inhibitor of metalloproteinase-1 (TIMP-1) has been suggested as a marker for abnormal regulation of tissue remodelling in type 1 diabetes. Metalloproteinase-9 (MMP-9) has been associated with matrix turnover, and Neutrophil gelatinase associated lipocalin (NGAL) is a marker of tubular injury in diabetic nephropathy. The aim was to analyse these biomarkers to unmask early diabetic complications. METHODS: Thirty-three type 1 diabetes patients, aged 20-35 years, and disease duration 20 ± 5.3 years were included. Along with clinical examination, neurophysiological measurements, routine biochemistry, plasma concentrations of TIMP-1, MMP-9 and NGAL were determined with immunoenzymatic techniques. RESULTS: TIMP-1 correlated with abnormal unilateral and bilateral vibratory sense foot perception (r = -0.49 and r = -0.51, respectively), foot neuropathy impairment assessment score (NIA; r = -0.55), neuropathy symptom assessment score (r = 0.42), microalbuminuria (r = 0.50) and eGFR (r = -0.45). MMP-9 correlated with impaired foot NIA (r = 0.51). Multiple regression analysis showed an association for TIMP-1 (p = 0.004) with impaired neurophysiological examinations and renal dysfunction along with NGAL (p = 0.016 and p = 0.015 respectively). CONCLUSIONS: This study suggests that plasma levels of TIMP-1, MMP-9 and NGAL may serve as useful biomarkers in unravelling subclinical neuropathy and nephropathy in type 1 diabetes.


Subject(s)
Diabetes Mellitus, Type 1/blood , Diabetic Nephropathies/blood , Diabetic Neuropathies/blood , Tissue Inhibitor of Metalloproteinase-1/blood , Adult , Biomarkers/blood , Cross-Sectional Studies , Diabetes Mellitus, Type 1/complications , Diabetes Mellitus, Type 1/diagnosis , Diabetic Nephropathies/diagnosis , Diabetic Nephropathies/etiology , Diabetic Neuropathies/diagnosis , Diabetic Neuropathies/etiology , Early Diagnosis , Female , Humans , Lipocalin-2/blood , Male , Matrix Metalloproteinase 9/blood , Predictive Value of Tests , Young Adult
3.
Toxicol In Vitro ; 27(2): 932-8, 2013 Mar.
Article in English | MEDLINE | ID: mdl-23318728

ABSTRACT

Cigarette smoking is a leading cause of cardiovascular disease. The cardiovascular effects of smoking are probably multifactorial, including effects on platelets. Previous reports investigating the effects of nicotine and tobacco on platelet function are inconsistent. The present study investigated in vitro effects of nicotine, its major metabolites, tobacco extracts and extract of tobacco-free snuff on human platelets. None of the metabolites cotinine, cotinine-N-oxide, nicotine-1'-N-oxide or trans-3'-hydroxycotinine (0.1-10 µM) affected platelet aggregation or P-selectin expression. Nicotine (10 µM) weakly increased platelet aggregation, whereas trans-3'-hydroxycotinine (0.1 µM) and nicotine-1'-N-oxide (1-10 µM) weakly inhibited adhesion to fibrinogen. To elucidate the influence of other tobacco compounds, we investigated the impact of moist tobacco and smoke extracts on platelet function. Filtered extracts of oral snuff, cigarette smoke and tobacco free snuff inhibited platelet adhesion concentration-dependently. The inhibitory effects of tobacco extracts on platelet adhesion were independent of nicotine content and the nitric-oxide-pathway and not mediated through a platelet-nicotine-receptor. Taken together, tobacco extracts inhibit platelet activation during short-term in vitro challenge. As only limited effects of nicotine and nicotine metabolites were seen, the tobacco-induced platelet inhibition are likely induced by other compounds present in tobacco and tobacco free snuff.


Subject(s)
Blood Platelets/drug effects , Cotinine/analogs & derivatives , Cotinine/toxicity , Nicotiana , Plant Extracts/toxicity , Blood Platelets/physiology , Cells, Cultured , Humans , Nicotine/analysis , Nicotine/toxicity , Plant Extracts/chemistry , Platelet Aggregation/drug effects
4.
Platelets ; 24(2): 129-35, 2013.
Article in English | MEDLINE | ID: mdl-22471400

ABSTRACT

Adrenaline is a platelet activator having a resting plasma concentration of <1 nmol/l that increases to a few nmol/l during stress. However, most in vitro assays only detect effects of adrenaline in micromolar concentrations. This makes it difficult to estimate the relevance of in vitro data for the in vivo situation. The aim of this study was to investigate experimental conditions in vitro that could detect platelet effects of adrenaline in nanomolar concentrations. Platelet adhesion to albumin and collagen was evaluated with a static platelet adhesion assay. Our results show that 10 nmol/l adrenaline induced platelet adhesion to albumin in platelet-rich plasma (PRP) prepared at 140 × g, while 100 nmol/l was necessary in order to increase adhesion of platelets prepared at 220 × g. The mean platelet volume was increased after preparation at 140 × g, suggesting that large reactive platelets contributed to the increased adrenaline sensitivity. At optimal Mg(2+)-concentration, adhesion to collagen was increased by 10 nmol/l adrenaline irrespective of centrifugal force applied during PRP preparation. More specifically, we defined two populations where adhesion to collagen was increased by 10 nmol/l adrenaline either upon centrifugation at 140 × g but not 220 × g or vice versa. In some experiments, platelet adhesion to collagen was induced by 3 nmol/l adrenaline, which corresponds to concentrations achieved during stress in vivo. In summary, the static adhesion assay is able to detect platelet activating effects of adrenaline very close to physiological concentrations. This is rare for in vitro assays and motivates further research about adrenergic signalling in platelets.


Subject(s)
Blood Platelets/drug effects , Blood Platelets/physiology , Epinephrine/pharmacology , Platelet Activating Factor/pharmacology , Platelet Adhesiveness/drug effects , Albumins/metabolism , Collagen/metabolism , Humans , Platelet Count
5.
Pharmacol Rep ; 64(4): 979-83, 2012.
Article in English | MEDLINE | ID: mdl-23087151

ABSTRACT

BACKGROUND: Although several studies show that there is an increased risk of bleeding events during antidepressant treatment with selective serotonin reuptake inhibitors (SSRIs), few studies show direct effects in vitro of SSRIs on hemostasis. METHODS: This study was undertaken to investigate the effects on platelet adhesion and plasma coagulation (APTT and PT) of two common SSRIs, citalopram and sertraline, the selective noradrenaline reuptake inhibitor reboxetine, and the serotonin and noradrenaline reuptake inhibitor venlafaxine. RESULTS: None of the compounds affected plasma coagulation significantly but all compounds except for venlafaxine inhibited platelet adhesion by approximately 50% or more at the highest concentration (100 µg/l, p < 0.01). The potency of respective compound to inhibit platelet adhesion to both collagen and fibrinogen surfaces was in the following order; citalopram > sertraline > reboxetine. In contrast, venlafaxine caused a weak but statistically significant increased platelet adhesion to fibrinogen. CONCLUSION: This study showed that sertraline, citalopram and reboxetine direct and acutely decrease platelet adhesion to both collagen and fibrinogen in vitro. These results also indicate that increased risk for bleeding complications in antidepressant users may not only be explained by depletion of serotonin in platelets.


Subject(s)
Adrenergic Uptake Inhibitors/pharmacology , Blood Coagulation/drug effects , Blood Platelets/drug effects , Norepinephrine/antagonists & inhibitors , Platelet Adhesiveness/drug effects , Selective Serotonin Reuptake Inhibitors/pharmacology , Serotonin/metabolism , Adult , Antidepressive Agents/pharmacology , Blood Platelets/metabolism , Citalopram/pharmacology , Cyclohexanols/pharmacology , Female , Fibrinogen/metabolism , Humans , Male , Middle Aged , Morpholines/pharmacology , Reboxetine , Sertraline/pharmacology , Venlafaxine Hydrochloride , Young Adult
6.
Phytother Res ; 24(9): 1297-301, 2010 Sep.
Article in English | MEDLINE | ID: mdl-20148408

ABSTRACT

Extract from seeds and bark of horse chestnut (Aesculus hippocastanum L) is used as an herbal medicine against chronic venous insufficiency. The effect and mechanism of action on veins, arteries, and platelets are not fully understood. The aim of this study was to investigate the effects and mechanisms of action of horse chestnut on the contraction of bovine mesenteric veins and arteries, and human platelet aggregation. Contraction studies showed that horse chestnut extract dose-dependently contracted both veins and arteries, with the veins being the most sensitive. Contraction of both veins and arteries were significantly inhibited by the 5-HT(2A) receptor antagonist ketanserin. No effect on contraction was seen with the cyclooxygenase inhibitor indomethacin, the alpha(1) receptor antagonist prazosin or the angiotensin AT(1) receptor antagonist saralasin neither in veins nor arteries. ADP-induced human platelet aggregation was significantly reduced by horse chestnut. A further reduction was seen with the extract in the presence of ketanserin. In conclusion, horse chestnut contraction of both veins and arteries is, at least partly, mediated through 5-HT(2A) receptors. Human platelet aggregation is reduced by horse chestnut. The clinical importance of these findings concerning clinical use, possible adverse effects, and drug interactions remains to be investigated.


Subject(s)
Aesculus , Muscle Contraction/drug effects , Muscle, Smooth, Vascular/drug effects , Plant Extracts/pharmacology , Platelet Aggregation/drug effects , Receptor, Serotonin, 5-HT2A/metabolism , Serotonin 5-HT2 Receptor Agonists/pharmacology , Adenosine Diphosphate , Adrenergic alpha-1 Receptor Antagonists/pharmacology , Angiotensin II Type 1 Receptor Blockers/pharmacology , Animals , Cattle , Cyclooxygenase Inhibitors/pharmacology , Dose-Response Relationship, Drug , Humans , Ketanserin/pharmacology , Mesenteric Arteries/drug effects , Mesenteric Veins/drug effects , Plant Bark , Platelet Aggregation Inhibitors/pharmacology , Seeds , Serotonin 5-HT2 Receptor Antagonists/pharmacology
7.
Turk J Haematol ; 27(2): 82-90, 2010 Jun 05.
Article in English | MEDLINE | ID: mdl-27263449

ABSTRACT

OBJECTIVE: Essential thrombocythemia (ET) is a chronic myeloproliferative disorder characterized by elevated platelet counts and increased risk of thrombosis. Ex vivo data suggest increased platelet reactivity in agreement with the increased thrombosis risk, while in vitro tests often detect decreased platelet activity. The present study aimed to investigate adhesion of ET-platelets in vitro, which is an aspect of platelet function that has been addressed in only a few studies on ET patients. METHODS: The study included 30 ET patients and 14 healthy controls. Platelet adhesion was measured with a static platelet adhesion assay. RESULTS: The main finding was that ET-platelets were more readily activated by adhesion-inducing stimuli in vitro than control platelets. This was particularly evident in elderly patients and when using multiple stimuli, such as surfaces of collagen or fibrinogen combined with addition of adenosine 5'-diphosphate or ristocetin. Such multiple stimuli resulted in adhesion above the control mean +2 standard deviations for approximately 50% of the patients. CONCLUSION: The results are in accordance with the concept of increased platelet activity in ET, but opposite to most other in vitro studies. We suggest that the conditions in the adhesion assay might mimic the in vivo situation regarding the presence of chronic platelet activation.

8.
Blood Coagul Fibrinolysis ; 20(3): 197-206, 2009 Apr.
Article in English | MEDLINE | ID: mdl-19657317

ABSTRACT

Platelet adhesion is a complex and important event for prevention of blood loss after vessel injury. This study investigated fundamental adhesive mechanisms occurring in an in-vitro assay developed for the measurement of static adhesion of human platelets in plasma. The aim was to gain methodological knowledge that could be used for interpretations of results from other studies using this specific assay. Involvement of adhesive receptors was investigated by the use of various antibodies as well as therapeutic drugs (abciximab, eptifibatide and tirofiban). Inhibitors of adenosine 5'-diphosphate receptors (cangrelor, MRS2179) and of thromboxane A(2) signalling (BM-531) were used to estimate the role of autocrine activation. Adhesion to collagen was found to be mainly mediated by alpha(2)beta(1) and to some extent by alpha(IIb)beta(3). Adhesion to fibrinogen was mediated by alpha(IIb)beta(3). In addition, adenosine 5'-diphosphate-induced adhesion to albumin was dependent on alpha(IIb)beta(3). Furthermore, experiments with cangrelor and BM-531 showed that the majority of the adhesive interactions tested were dependent on adenosine 5'-diphosphate or thromboxane A(2). We conclude that the mechanisms of adhesion measured by the static platelet adhesion assay are in accordance with the current knowledge regarding platelet activation and adhesion. Despite its simplicity, we suggest that this adhesion assay could be used as a screening device for the study of the influence of various surfaces and soluble substances on platelet adhesion.


Subject(s)
Blood Platelets/physiology , Platelet Adhesiveness/physiology , Proteins/metabolism , Abciximab , Albumins/metabolism , Antibodies, Monoclonal/pharmacology , Blood Platelets/drug effects , Collagen/metabolism , Eptifibatide , Fibrinogen/metabolism , Humans , Immunoglobulin Fab Fragments/pharmacology , Peptides/pharmacology , Plasma , Platelet Adhesiveness/drug effects , Platelet Aggregation/drug effects , Purinergic P2 Receptor Antagonists , Receptors, Purinergic P2/blood , Thromboxane A2/blood , Tirofiban , Tyrosine/analogs & derivatives , Tyrosine/pharmacology
9.
J Transl Med ; 7: 42, 2009 Jun 09.
Article in English | MEDLINE | ID: mdl-19508722

ABSTRACT

BACKGROUND: Despite the use of anti-platelet agents such as acetylsalicylic acid (ASA) and clopidogrel in coronary heart disease, some patients continue to suffer from atherothrombosis. This has stimulated development of platelet function assays to monitor treatment effects. However, it is still not recommended to change treatment based on results from platelet function assays. This study aimed to evaluate the capacity of a static platelet adhesion assay to detect platelet inhibiting effects of ASA and clopidogrel. The adhesion assay measures several aspects of platelet adhesion simultaneously, which increases the probability of finding conditions sensitive for anti-platelet treatment. METHODS: With a randomised cross-over design we evaluated the anti-platelet effects of ASA combined with clopidogrel as well as monotherapy with either drug alone in 29 patients with a recent acute coronary syndrome. Also, 29 matched healthy controls were included to evaluate intra-individual variability over time. Platelet function was measured by flow cytometry, serum thromboxane B2 (TXB2)-levels and by static platelet adhesion to different protein surfaces. The results were subjected to Principal Component Analysis followed by ANOVA, t-tests and linear regression analysis. RESULTS: The majority of platelet adhesion measures were reproducible in controls over time denoting that the assay can monitor platelet activity. Adenosine 5'-diphosphate (ADP)-induced platelet adhesion decreased significantly upon treatment with clopidogrel compared to ASA. Flow cytometric measurements showed the same pattern (r2 = 0.49). In opposite, TXB2-levels decreased with ASA compared to clopidogrel. Serum TXB2 and ADP-induced platelet activation could both be regarded as direct measures of the pharmacodynamic effects of ASA and clopidogrel respectively. Indirect pharmacodynamic measures such as adhesion to albumin induced by various soluble activators as well as SFLLRN-induced activation measured by flow cytometry were lower for clopidogrel compared to ASA. Furthermore, adhesion to collagen was lower for ASA and clopidogrel combined compared with either drug alone. CONCLUSION: The indirect pharmacodynamic measures of the effects of ASA and clopidogrel might be used together with ADP-induced activation and serum TXB2 for evaluation of anti-platelet treatment. This should be further evaluated in future clinical studies where screening opportunities with the adhesion assay will be optimised towards increased sensitivity to anti-platelet treatment.


Subject(s)
Aspirin/therapeutic use , Coronary Disease/blood , Coronary Disease/drug therapy , Platelet Adhesiveness , Platelet Aggregation Inhibitors/therapeutic use , Thromboxane B2/blood , Ticlopidine/analogs & derivatives , Aged , Aspirin/pharmacology , Case-Control Studies , Clopidogrel , Cross-Over Studies , Female , Fibrinogen/metabolism , Flow Cytometry , Health , Humans , Male , Middle Aged , P-Selectin/metabolism , Platelet Adhesiveness/drug effects , Platelet Aggregation Inhibitors/pharmacology , Principal Component Analysis , Regression Analysis , Ticlopidine/pharmacology , Ticlopidine/therapeutic use
10.
Clin Exp Pharmacol Physiol ; 34(8): 775-80, 2007 Aug.
Article in English | MEDLINE | ID: mdl-17600556

ABSTRACT

1. Several studies suggest an association between venous thromboembolism and the use of antipsychotic drugs, especially clozapine, but the biological mechanisms are unknown. It has been suggested that antipsychotic drugs enhance aggregation of platelets and thereby increase the risk of venous thrombosis. The purpose of the present study was to examine the effects of clozapine and its main metabolite, N-desmethyl clozapine, as well as olanzapine, risperidone and haloperidol, on platelet adhesion and aggregation and on plasma coagulation in vitro. 2. Blood was collected from healthy subjects free of medication. Platelet adhesion to different protein surfaces and aggregation were measured in microplates. The coagulation methods of activated partial thromboplastin time (APTT) and prothrombin time were performed in platelet-poor plasma. 3. Clozapine was the only compound that increased platelet adhesion and aggregation and shortened APTT. The effect appeared at therapeutic concentrations and was significant but weak. 4. This weak effect of clozapine on haemostasis may explain, in part, the association of this compound and venous thromboembolism.


Subject(s)
Antipsychotic Agents/pharmacology , Blood Coagulation/drug effects , Blood Platelets/drug effects , Clozapine/pharmacology , Platelet Adhesiveness/drug effects , Platelet Aggregation/drug effects , Adult , Aged , Antipsychotic Agents/adverse effects , Benzodiazepines/pharmacology , Clozapine/adverse effects , Clozapine/analogs & derivatives , Dose-Response Relationship, Drug , Female , Haloperidol/pharmacology , Humans , In Vitro Techniques , Male , Middle Aged , Olanzapine , Partial Thromboplastin Time , Prothrombin Time , Risperidone/pharmacology , Thromboembolism/blood , Thromboembolism/chemically induced , Venous Thrombosis/blood , Venous Thrombosis/chemically induced
11.
Blood Coagul Fibrinolysis ; 17(5): 359-68, 2006 Jul.
Article in English | MEDLINE | ID: mdl-16788312

ABSTRACT

Lysophosphatidic acid (LPA) and adrenaline are weak platelet activators considered important for thrombus formation, and were previously shown to synergistically increase platelet aggregation. Here we investigate synergistic activation by LPA and adrenaline when measuring platelet adhesion. Platelet-rich plasma from healthy blood donors together with adrenaline and/or LPA were added to protein-coated microplates. Platelets were allowed to adhere and the amount of adhesion detected enzymatically. The LPA and adrenaline combination induced a synergistic increase of platelet adhesion to a normally non-adhesive albumin surface. The degree of synergy varied markedly between individuals; these variations could not be explained by age, gender, blood type or different amounts of platelets, oxidized low-density lipoprotein, insulin or glucose in plasma. There was a trend indicating increased synergistic effect for platelets sensitive to adrenaline stimulation. The synergistic effect was blocked by the alpha2-adrenoceptor antagonist yohimbine and inhibited by the ADP scavenger system creatine phosphate/creatine phosphokinase and antibodies against alphaIIbbeta3. Furthermore, platelets adhering to albumin after adrenaline and LPA treatment expressed P-selectin. In conclusion, LPA and adrenaline act synergistically to increase alphaIIbbeta3-mediated platelet adhesion to albumin, dependent on alpha2-adrenoceptor signalling and platelet secretion. We also confirm that synergistic platelet activation achieved with LPA and adrenaline is highly donor dependent.


Subject(s)
Albumins/physiology , Epinephrine/pharmacology , Lysophospholipids/pharmacology , Platelet Adhesiveness/drug effects , Adenosine Diphosphate/antagonists & inhibitors , Albumins/metabolism , Autoantibodies/physiology , Blood Donors , Blood Platelets/metabolism , Cell Adhesion/drug effects , Dose-Response Relationship, Drug , Drug Synergism , Humans , P-Selectin/biosynthesis , Platelet Glycoprotein GPIIb-IIIa Complex/immunology , Yohimbine/pharmacology
12.
J Pharmacol Toxicol Methods ; 52(3): 356-65, 2005.
Article in English | MEDLINE | ID: mdl-16005248

ABSTRACT

INTRODUCTION: Platelet adhesion is an initial, crucial and complex event for inhibiting blood loss upon vascular injury. Activation and adhesion of platelets also play a fundamental role in the development of thrombosis. A combination of exposed extracellular matrix proteins in the vascular wall and release of activating compounds from the participating cells activate the platelets. New potent anti-platelet agents are in progress but there is a shortage of methods that measure the concerted action of adhesive surfaces and soluble compounds upon platelet adhesion in vitro. The aim of this work was to develop a method to measure adhesion of platelets in plasma with standard laboratory equipment. METHODS: Platelet-rich plasma from healthy humans was used in studies to optimise the conditions of the present assay. Different proteins were coated in microplate wells and various soluble platelet activators and inhibitors were added to establish the ability of the current method to detect increased as well as decreased platelet adhesion. The amount of platelet adhesion was measured by the reaction between p-nitrophenyl phosphate and the intracellular enzyme acid phosphatase. RESULTS: Adhesion of platelets in plasma to microplate wells coated with albumin, collagen, fibrinogen and activated plasma showed significant surface dependency. The known soluble platelet activators adenosine diphosphate, adrenaline and ristocetin enhanced the levels of adhesion. Available anti-platelet agents such as prostacyclin, forskolin, acetylsalicylic acid and RGD containing peptides caused dose-dependent inhibition of platelet adhesion. DISCUSSION: This report describes a further development of a previously described method and offers the advantage to use platelets in plasma to measure platelet adhesion to protein surfaces. The assay is simple and flexible and is suitable in basic research for screening and characterisation of platelet adhesion responsiveness.


Subject(s)
Blood Platelets/physiology , Plasma/physiology , Platelet Adhesiveness , Proteins/metabolism , Adenosine Diphosphate/pharmacology , Albumins/metabolism , Blood Platelets/drug effects , Collagen/metabolism , Dose-Response Relationship, Drug , Drug Evaluation, Preclinical/methods , Epinephrine/pharmacology , Fibrinogen/metabolism , Humans , In Vitro Techniques , Inhibitory Concentration 50 , Platelet Adhesiveness/drug effects , Platelet Aggregation Inhibitors/pharmacology , Regression Analysis , Reproducibility of Results , Ristocetin/pharmacology
SELECTION OF CITATIONS
SEARCH DETAIL
...